Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed Refractory Multiple Myeloma (RRMM)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT06961669
What this trial is testing

Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma

Who this might be right for
Lymphoblastic LeukemiaRelapsed or Refractory Multiple Myeloma (RRMM)
Anhui Provincial Hospital 18
Testing effectiveness (Phase 2)WithdrawnNCT05647512
What this trial is testing

Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases

Who this might be right for
Relapsed or Refractory Multiple MyelomaOther Plasma Cell Diseases
LaNova Medicines Limited
Not applicableStudy completedNCT05673967
What this trial is testing

Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed and Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals 62
Early research (Phase 1)Active Not RecruitingNCT07809594
What this trial is testing

CS1-Targeted CAR-T Cells for Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma (RRMM)Plasma Cell Myeloma
Institute of Hematology & Blood Diseases Hospital, China 10
Testing effectiveness (Phase 2)Looking for participantsNCT07382739
What this trial is testing

Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

Who this might be right for
Phase 2Radiotherapy-Induced Immune PrimingElranatamab+4 more
M.D. Anderson Cancer Center 34
Testing effectiveness (Phase 2)Active Not RecruitingNCT07217119
What this trial is testing

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 25
Not applicableNo Longer AvailableNCT05462639
What this trial is testing

Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Pfizer
Testing effectiveness (Phase 2)Looking for participantsNCT06115135
What this trial is testing

Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Oncotherapeutics 39
Early research (Phase 1)Active Not RecruitingNCT04398745
What this trial is testing

Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 36
Testing effectiveness (Phase 2)Ended earlyNCT06160609
What this trial is testing

Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM

Who this might be right for
Relapsed/Refractory Multiple Myeloma
GlaxoSmithKline 9
Testing effectiveness (Phase 2)Study completedNCT04191616
What this trial is testing

Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Amgen 54
Testing effectiveness (Phase 2)Looking for participantsNCT06645678
What this trial is testing

Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Relapsed Refractory Multiple Myeloma (RRMM)
YOUNGIL KOH 75
Early research (Phase 1)Looking for participantsNCT07558915
What this trial is testing

Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed/Refractory Multiple Myeloma
Genentech, Inc. 160
Early research (Phase 1)Ended earlyNCT03582033
What this trial is testing

A Safety Study of SEA-BCMA in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Seagen Inc. 83
Testing effectiveness (Phase 2)Looking for participantsNCT06103838
What this trial is testing

18F-Fluciclovine PET/CT in Multiple Myeloma

Who this might be right for
Multiple MyelomaNewly Diagnosed Multiple Myeloma (NDMM)Relapsed and/or Refractory Multiple Myeloma (RRMM)
National Cancer Institute (NCI) 60
Testing effectiveness (Phase 2)UnknownNCT04941937
What this trial is testing

Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM

Who this might be right for
Multiple Myeloma
Juan Du 90
Very early researchNot Yet RecruitingNCT07234721
What this trial is testing

SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed and Refractory Multiple Myeloma (RRMM)
Institute of Hematology & Blood Diseases Hospital, China 9
Early research (Phase 1)Not Yet RecruitingNCT07622862
What this trial is testing

Exploratory Clinical Trial of DQ1001 in Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma RefractoryMultiple Myeloma Progression
Zhongshan Hospital (Xiamen), Fudan University 16
Large-scale testing (Phase 3)WithdrawnNCT06232707
What this trial is testing

Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma
Celgene
Testing effectiveness (Phase 2)Study completedNCT03544281
What this trial is testing

To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 153
Next Page